There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Author and article information

Journal

PubMed ID:: 19191685

ScienceOpen disciplines: Endocrinology & Diabetes,Medicine

Data availability:

ScienceOpen disciplines: Endocrinology & Diabetes, Medicine

Comments

Comment on this article

Cited by 4

Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial
Authors: K Kaku, K Enya, R Nakaya …
Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes
Authors: Enrique Z Fisman, Alexander Tenenbaum
Choosing a Gliptin
Authors: Vishal Gupta, Sanjay Kalra

See all cited by

Alogliptin: a new, highly selective dipeptidyl peptidase‐4 inhibitor for the treatment of type diabetes

Read this article at